studies

metastatic-recurrent HNSCC (mHNSCC), pembrolizumab based treatment vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsKEYNOTE-040 (all population), 2018 0.80 [0.65; 0.98] KEYNOTE-040 (CPS >1), 2018 0.74 [0.58; 0.94] KEYNOTE-048 (P vs C ; all population), 2019 0.83 [0.70; 0.99] KEYNOTE-048 (P vs C ; CPS > 1), 2019 0.78 [0.64; 0.96] KEYNOTE-048 (P vs C ; CPS > 20), 2019 0.61 [0.45; 0.83] KEYNOTE-048 (PC vs C ; all population), 2019 0.77 [0.63; 0.94] KEYNOTE-048 (PC vs C ; CPS > 1), 2019 0.63 [0.51; 0.77] KEYNOTE-048 (PC vs C ; CPS > 20), 2019 0.60 [0.44; 0.81] 0.74[0.68; 0.80]KEYNOTE-040 (all population), 2018, KEYNOTE-040 (CPS >1), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (P vs C ; CPS > 1), 2019, KEYNOTE-048 (P vs C ; CPS > 20), 2019, KEYNOTE-048 (PC vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; CPS > 1), 2019, KEYNOTE-048 (PC vs C ; CPS > 20), 2019817%3,513moderateserious deaths (OS) (extension)detailed resultsKEYNOTE-048 (P vs C ; CPS > 1), 2019 0.74 [0.61; 0.90] KEYNOTE-048 (P vs C ; CPS > 20), 2019 0.58 [0.44; 0.77] KEYNOTE-048 (PC vs C ; all population), 2019 0.72 [0.60; 0.87] 0.70[0.62; 0.79]KEYNOTE-048 (P vs C ; CPS > 1), 2019, KEYNOTE-048 (P vs C ; CPS > 20), 2019, KEYNOTE-048 (PC vs C ; all population), 201933%1,326moderatenot evaluable progression or deaths (PFS)detailed resultsKEYNOTE-040 (all population), 2018 0.96 [0.79; 1.16] KEYNOTE-040 (CPS >1), 2018 1.01 [0.81; 1.26] KEYNOTE-048 (P vs C ; all population), 2019 1.34 [1.13; 1.59] KEYNOTE-048 (P vs C ; CPS > 1), 2019 1.16 [0.96; 1.40] KEYNOTE-048 (P vs C ; CPS > 20), 2019 0.99 [0.75; 1.30] KEYNOTE-048 (PC vs C ; all population), 2019 0.92 [0.77; 1.10] KEYNOTE-048 (PC vs C ; CPS > 1), 2019 0.82 [0.67; 1.00] KEYNOTE-048 (PC vs C ; CPS > 20), 2019 0.73 [0.55; 0.97] 0.99[0.86; 1.13]KEYNOTE-040 (all population), 2018, KEYNOTE-040 (CPS >1), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (P vs C ; CPS > 1), 2019, KEYNOTE-048 (P vs C ; CPS > 20), 2019, KEYNOTE-048 (PC vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; CPS > 1), 2019, KEYNOTE-048 (PC vs C ; CPS > 20), 2019870%3,513moderatenot evaluable objective responses (ORR)detailed resultsKEYNOTE-040 (all population), 2018 1.52 [0.88; 2.62] KEYNOTE-040 (CPS >1), 2018 1.90 [1.04; 3.47] KEYNOTE-048 (P vs C ; all population), 2019 0.36 [0.25; 0.53] KEYNOTE-048 (P vs C ; CPS > 1), 2019 0.44 [0.29; 0.66] KEYNOTE-048 (P vs C ; CPS > 20), 2019 0.11 [0.06; 0.20] KEYNOTE-048 (PC vs C ; all population), 2019 0.97 [0.69; 1.37] KEYNOTE-048 (PC vs C ; CPS > 1), 2019 1.03 [0.71; 1.49] KEYNOTE-048 (PC vs C ; CPS > 20), 2019 1.21 [0.72; 2.05] 0.71[0.40; 1.23]KEYNOTE-040 (all population), 2018, KEYNOTE-040 (CPS >1), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (P vs C ; CPS > 1), 2019, KEYNOTE-048 (P vs C ; CPS > 20), 2019, KEYNOTE-048 (PC vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; CPS > 1), 2019, KEYNOTE-048 (PC vs C ; CPS > 20), 2019892%3,522moderatenot evaluable AE (any grade)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.31 [0.22; 0.44] 0.31[0.22; 0.44]KEYNOTE-048 (P vs C ; all population), 201910%587NAnot evaluable AE (grade 3-4)detailed resultsKEYNOTE-048 (PC vs C ; all population), 2019 1.00 [0.69; 1.46] 1.00[0.69; 1.46]KEYNOTE-048 (PC vs C ; all population), 201910%563NAnot evaluable AE leading to death (grade 5)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.84 [0.48; 1.48] KEYNOTE-048 (PC vs C ; all population), 2019 1.21 [0.71; 2.07] 1.02[0.69; 1.50]KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 201920%1,150moderatenot evaluable AE leading to treatment discontinuation (any grade)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.36 [0.23; 0.55] KEYNOTE-048 (PC vs C ; all population), 2019 1.27 [0.89; 1.83] 0.68[0.20; 2.35]KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019295%1,150moderatenot evaluable TRAE (any grade)detailed resultsKEYNOTE-040 (all population), 2018 0.33 [0.21; 0.51] KEYNOTE-048 (P vs C ; all population), 2019 0.05 [0.02; 0.09] KEYNOTE-048 (PC vs C ; all population), 2019 0.71 [0.30; 1.72] 0.22[0.05; 0.93]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019393%1,630moderatenot evaluable TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.24 [0.15; 0.39] KEYNOTE-048 (P vs C ; all population), 2019 0.09 [0.06; 0.13] KEYNOTE-048 (PC vs C ; all population), 2019 1.12 [0.78; 1.61] 0.29[0.06; 1.37]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019398%1,630moderatenot evaluable TRAE leading to death (grade 5)detailed resultsKEYNOTE-040 (all population), 2018 1.92 [0.35; 10.57] KEYNOTE-048 (P vs C ; all population), 2019 0.35 [0.09; 1.34] KEYNOTE-048 (PC vs C ; all population), 2019 1.45 [0.57; 3.65] 0.99[0.37; 2.63]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019343%1,630moderatenot evaluable TRAE leading to discontinuation (any grade)detailed resultsKEYNOTE-040 (all population), 2018 1.20 [0.55; 2.62] 1.20[0.55; 2.62]KEYNOTE-040 (all population), 201810%480NAnot evaluable TRAE leading to discontinuation (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 1.28 [0.53; 3.10] 1.28[0.53; 3.10]KEYNOTE-040 (all population), 201810%480NAnot evaluable Acute kidney injury TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 1.91 [0.06; 57.09] 1.91[0.06; 57.09]KEYNOTE-040 (all population), 201810%480NAnot evaluable Adrenal insufficiency TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] KEYNOTE-048 (P vs C ; all population), 2019 1.92 [0.06; 57.35] KEYNOTE-048 (PC vs C ; all population), 2019 1.04 [0.02; 52.60] 1.29[0.15; 11.09]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 201930%1,630moderatenot evaluable Alopecia TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Anaemia TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.10 [0.01; 0.81] KEYNOTE-048 (P vs C ; all population), 2019 0.04 [0.01; 0.16] KEYNOTE-048 (PC vs C ; all population), 2019 1.38 [0.89; 2.14] 0.19[0.01; 2.67]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019393%1,630moderatenot evaluable Arthralgia TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Asthenia TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.23 [0.03; 2.12] KEYNOTE-048 (P vs C ; all population), 2019 0.16 [0.02; 1.31] KEYNOTE-048 (PC vs C ; all population), 2019 1.22 [0.40; 3.67] 0.47[0.12; 1.88]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019347%1,630moderatenot evaluable Blood and lymphatic system disorders TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.04 [0.01; 0.31] KEYNOTE-048 (P vs C ; all population), 2019 0.02 [0.01; 0.07] KEYNOTE-048 (PC vs C ; all population), 2019 1.30 [0.92; 1.82] 0.12[0.01; 2.59]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019397%1,630moderatenot evaluable Blood creatinine increased TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] KEYNOTE-048 (P vs C ; all population), 2019 0.96 [0.02; 48.37] KEYNOTE-048 (PC vs C ; all population), 2019 2.08 [0.07; 62.36] 1.30[0.15; 11.18]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 201930%1,630moderatenot evaluable Cardiac disorders TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Chills TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Colitis TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] KEYNOTE-048 (P vs C ; all population), 2019 0.96 [0.13; 6.84] KEYNOTE-048 (PC vs C ; all population), 2019 1.04 [0.15; 7.44] 0.99[0.27; 3.68]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 201930%1,630moderatenot evaluable Constipation TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.47 [0.02; 14.21] KEYNOTE-048 (P vs C ; all population), 2019 0.96 [0.02; 48.37] KEYNOTE-048 (PC vs C ; all population), 2019 1.04 [0.02; 52.60] 0.74[0.09; 6.36]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 201930%1,630moderatenot evaluable Cough TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Decreased appetite TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 1.91 [0.06; 57.09] KEYNOTE-048 (P vs C ; all population), 2019 0.12 [0.01; 0.94] KEYNOTE-048 (PC vs C ; all population), 2019 1.59 [0.64; 3.94] 0.71[0.11; 4.40]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019361%1,630moderatenot evaluable Diarrhoea TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 3.85 [0.43; 34.71] KEYNOTE-048 (P vs C ; all population), 2019 0.19 [0.02; 1.62] KEYNOTE-048 (PC vs C ; all population), 2019 0.62 [0.15; 2.62] 0.74[0.16; 3.32]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019347%1,630moderatenot evaluable Dyspepsia TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Dyspnoea TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 3.83 [0.17; 85.33] 3.83[0.17; 85.33]KEYNOTE-040 (all population), 201810%480NAnot evaluable Endocrine disorders TRAE (grade 3-4) detailed resultsKEYNOTE-040 (all population), 2018 1.91 [0.06; 57.09] KEYNOTE-048 (P vs C ; all population), 2019 5.79 [0.29; 116.06] KEYNOTE-048 (PC vs C ; all population), 2019 2.08 [0.07; 62.36] 3.02[0.46; 19.73]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 201930%1,630moderatenot evaluable Epistaxis TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Eye disorders TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Fatigue TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 1.92 [0.35; 10.57] KEYNOTE-048 (P vs C ; all population), 2019 0.25 [0.07; 0.92] KEYNOTE-048 (PC vs C ; all population), 2019 1.85 [0.87; 3.97] 0.98[0.26; 3.68]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019372%1,630moderatenot evaluable Febrile neutropenia TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.05 [0.00; 0.79] 0.05[0.00; 0.79]KEYNOTE-040 (all population), 201810%480NAnot evaluable Gastritis TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed resultsKEYNOTE-040 (all population), 2018 0.35 [0.14; 0.86] KEYNOTE-048 (P vs C ; all population), 2019 0.07 [0.02; 0.23] 0.17[0.03; 0.80]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019278%1,067moderatenot evaluable General disorders and administration site conditions TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.57 [0.23; 1.40] KEYNOTE-048 (P vs C ; all population), 2019 0.19 [0.08; 0.46] KEYNOTE-048 (PC vs C ; all population), 2019 1.90 [1.15; 3.13] 0.61[0.15; 2.52]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019390%1,630moderatenot evaluable Guillain-Barré syndrome TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 1.91 [0.06; 57.09] 1.91[0.06; 57.09]KEYNOTE-040 (all population), 201810%480NAnot evaluable Headache TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.47 [0.02; 14.21] 0.47[0.02; 14.21]KEYNOTE-040 (all population), 201810%480NAnot evaluable Hepatitis TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 2.01 [0.07; 60.26] KEYNOTE-048 (P vs C ; all population), 2019 3.85 [0.17; 85.65] KEYNOTE-048 (PC vs C ; all population), 2019 2.08 [0.07; 62.36] 2.59[0.39; 17.34]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 201930%1,645moderatenot evaluable Hepatobiliary disorders TRAE (grade 3-4) detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.06; 15.29] 0.95[0.06; 15.29]KEYNOTE-040 (all population), 201810%480NAnot evaluable Hypersensitivity TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Hypertension TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Hyperthyroidism TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] KEYNOTE-048 (P vs C ; all population), 2019 1.92 [0.06; 57.35] KEYNOTE-048 (PC vs C ; all population), 2019 1.04 [0.02; 52.60] 1.29[0.15; 11.09]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 201930%1,630moderatenot evaluable Hypophysitis TRAE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 1.92 [0.06; 57.35] KEYNOTE-048 (PC vs C ; all population), 2019 2.08 [0.07; 62.36] 2.00[0.18; 22.10]KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 201920%1,150moderatenot evaluable Hypothyroidism TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 1.91 [0.06; 57.09] KEYNOTE-048 (PC vs C ; all population), 2019 1.04 [0.02; 52.60] 1.47[0.11; 19.19]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (PC vs C ; all population), 201920%1,043moderatenot evaluable Increase AST TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.31 [0.03; 3.04] 0.31[0.03; 3.04]KEYNOTE-040 (all population), 201810%480NAnot evaluable Increased ALT TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.16 [0.01; 3.15] 0.16[0.01; 3.15]KEYNOTE-040 (all population), 201810%480NAnot evaluable Infusion-related reactions TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] KEYNOTE-048 (P vs C ; all population), 2019 0.31 [0.06; 1.57] KEYNOTE-048 (PC vs C ; all population), 2019 0.34 [0.07; 1.71] 0.36[0.12; 1.06]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 201930%1,630moderatenot evaluable Leucopenia TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.07 [0.00; 1.17] KEYNOTE-048 (P vs C ; all population), 2019 0.03 [0.00; 0.47] KEYNOTE-048 (PC vs C ; all population), 2019 0.51 [0.21; 1.20] 0.15[0.02; 1.03]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019360%1,630moderatenot evaluable Maculopapular rash TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.47 [0.02; 14.21] 0.47[0.02; 14.21]KEYNOTE-040 (all population), 201810%480NAnot evaluable Metabolism and nutrition disorders TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.40 [0.10; 1.57] KEYNOTE-048 (P vs C ; all population), 2019 0.26 [0.14; 0.49] KEYNOTE-048 (PC vs C ; all population), 2019 0.88 [0.55; 1.41] 0.47[0.19; 1.17]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019379%1,630moderatenot evaluable Mucosal inflammation TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.19 [0.02; 1.61] KEYNOTE-048 (P vs C ; all population), 2019 0.13 [0.03; 0.58] KEYNOTE-048 (PC vs C ; all population), 2019 2.03 [1.04; 3.97] 0.42[0.05; 3.31]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019385%1,630moderatenot evaluable Musculoskeletal and connective tissue disorders TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 1.91 [0.06; 57.09] 1.91[0.06; 57.09]KEYNOTE-040 (all population), 201810%480NAnot evaluable Myalgia TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Myocarditis TRAE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.96 [0.02; 48.37] KEYNOTE-048 (PC vs C ; all population), 2019 2.08 [0.07; 62.36] 1.49[0.11; 19.48]KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 201920%1,150moderatenot evaluable Myositis TRAE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.48 [0.02; 14.29] KEYNOTE-048 (PC vs C ; all population), 2019 0.52 [0.02; 15.54] 0.50[0.05; 5.51]KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 201920%1,150moderatenot evaluable Nausea TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.47 [0.02; 14.21] KEYNOTE-048 (P vs C ; all population), 2019 0.03 [0.00; 0.47] KEYNOTE-048 (PC vs C ; all population), 2019 0.97 [0.47; 2.01] 0.31[0.03; 2.80]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019365%1,630moderatenot evaluable Nephritis TRAE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 3.85 [0.17; 85.65] KEYNOTE-048 (PC vs C ; all population), 2019 1.04 [0.02; 52.60] 2.32[0.20; 26.51]KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 201920%1,150moderatenot evaluable Nervous system disorders TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.47 [0.04; 5.26] 0.47[0.04; 5.26]KEYNOTE-040 (all population), 201810%480NAnot evaluable Neutropenia TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.04 [0.01; 0.33] KEYNOTE-048 (P vs C ; all population), 2019 0.01 [0.00; 0.11] KEYNOTE-048 (PC vs C ; all population), 2019 0.85 [0.56; 1.30] 0.08[0.00; 1.60]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019389%1,630moderatenot evaluable Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Pancreatitis TRAE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.96 [0.02; 48.37] KEYNOTE-048 (PC vs C ; all population), 2019 2.08 [0.07; 62.36] 1.49[0.11; 19.48]KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 201920%1,150moderatenot evaluable Pancytopenia TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.16 [0.01; 3.15] 0.16[0.01; 3.15]KEYNOTE-040 (all population), 201810%480NAnot evaluable Paraesthesia TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Peripheral oedema TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 1.91 [0.06; 57.09] 1.91[0.06; 57.09]KEYNOTE-040 (all population), 201810%480NAnot evaluable Pneumonitis TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.06; 15.29] KEYNOTE-048 (P vs C ; all population), 2019 2.42 [0.46; 12.55] KEYNOTE-048 (PC vs C ; all population), 2019 2.63 [0.51; 13.67] 2.18[0.74; 6.38]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 201930%1,630moderatenot evaluable Pruritic rash TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Pruritus generalised TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Pruritus TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.24 [0.01; 5.27] 0.24[0.01; 5.27]KEYNOTE-040 (all population), 201810%480NAnot evaluable Pyrexia TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Rash TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.06; 15.29] KEYNOTE-048 (P vs C ; all population), 2019 0.11 [0.02; 0.47] KEYNOTE-048 (PC vs C ; all population), 2019 0.06 [0.01; 0.44] 0.13[0.04; 0.50]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019325%1,630moderatenot evaluable Renal and urinary disorders TRAE (grade 3-4) detailed resultsKEYNOTE-040 (all population), 2018 1.91 [0.06; 57.09] 1.91[0.06; 57.09]KEYNOTE-040 (all population), 201810%480NAnot evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed resultsKEYNOTE-040 (all population), 2018 1.44 [0.40; 5.16] 1.44[0.40; 5.16]KEYNOTE-040 (all population), 201810%480NAnot evaluable Sepsis TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.24 [0.01; 5.27] 0.24[0.01; 5.27]KEYNOTE-040 (all population), 201810%480NAnot evaluable Severe skin reaction TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.54 [0.15; 1.86] KEYNOTE-048 (P vs C ; all population), 2019 0.29 [0.11; 0.73] KEYNOTE-048 (PC vs C ; all population), 2019 0.10 [0.02; 0.45] 0.27[0.12; 0.61]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019330%1,630moderatenot evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed resultsKEYNOTE-040 (all population), 2018 0.31 [0.08; 1.15] KEYNOTE-048 (PC vs C ; all population), 2019 0.11 [0.03; 0.35] 0.17[0.06; 0.50]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (PC vs C ; all population), 2019227%1,043moderatenot evaluable Skin exfoliation TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Stevens-Johnson syndrome TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Stomatitis TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.08 [0.01; 0.65] KEYNOTE-048 (P vs C ; all population), 2019 0.05 [0.00; 0.80] KEYNOTE-048 (PC vs C ; all population), 2019 2.40 [1.11; 5.16] 0.26[0.02; 4.41]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019386%1,630moderatenot evaluable Thrombocytopenia TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.09 [0.01; 1.72] KEYNOTE-048 (P vs C ; all population), 2019 0.04 [0.00; 0.27] KEYNOTE-048 (PC vs C ; all population), 2019 1.04 [0.58; 1.89] 0.18[0.02; 2.20]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019383%1,630moderatenot evaluable Thyroiditis TRAE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.96 [0.02; 48.37] KEYNOTE-048 (PC vs C ; all population), 2019 1.04 [0.02; 52.60] 1.00[0.06; 15.99]KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 201920%1,150moderatenot evaluable Uveitis TRAE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.96 [0.02; 48.37] KEYNOTE-048 (PC vs C ; all population), 2019 1.04 [0.02; 52.60] 1.00[0.06; 15.99]KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 201920%1,150moderatenot evaluable Vascular disorders TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Vomiting TRAE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.09 [0.01; 1.73] KEYNOTE-048 (PC vs C ; all population), 2019 1.47 [0.46; 4.68] 0.52[0.04; 7.08]KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019266%1,150moderatenot evaluable Weight decreased TRAE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] KEYNOTE-048 (P vs C ; all population), 2019 0.96 [0.06; 15.37] KEYNOTE-048 (PC vs C ; all population), 2019 2.09 [0.19; 23.16] 1.38[0.26; 7.18]KEYNOTE-040 (all population), 2018, KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 201930%1,630moderatenot evaluable Abdominal pain AE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.19 [0.02; 1.62] KEYNOTE-048 (PC vs C ; all population), 2019 0.41 [0.08; 2.14] 0.31[0.08; 1.14]KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 201920%1,150moderatenot evaluable Acute kidney injury AE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 1.93 [0.35; 10.60] KEYNOTE-048 (PC vs C ; all population), 2019 2.63 [0.51; 13.67] 2.26[0.69; 7.40]KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 201920%1,150moderatenot evaluable Anaemia AE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.24 [0.13; 0.44] KEYNOTE-048 (PC vs C ; all population), 2019 1.65 [1.10; 2.49] 0.64[0.10; 4.24]KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019296%1,150moderatenot evaluable Asthenia AE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.31 [0.08; 1.16] KEYNOTE-048 (PC vs C ; all population), 2019 1.04 [0.41; 2.66] 0.62[0.19; 2.01]KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019253%1,150moderatenot evaluable Back pain AE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Blood and lymphatic system disorders AE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.10 [0.06; 0.18] KEYNOTE-048 (PC vs C ; all population), 2019 1.39 [1.00; 1.94] 0.38[0.03; 4.87]KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019299%1,150moderatenot evaluable Decreased appetite AE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.28 [0.08; 1.03] KEYNOTE-048 (PC vs C ; all population), 2019 1.37 [0.59; 3.18] 0.67[0.14; 3.15]KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019275%1,150moderatenot evaluable Diarrhoea AE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.23 [0.05; 1.11] KEYNOTE-048 (PC vs C ; all population), 2019 1.04 [0.39; 2.81] 0.56[0.13; 2.37]KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019260%1,150moderatenot evaluable Dizziness AE (grade 3-4)detailed resultsKEYNOTE-040 (all population), 2018 0.95 [0.02; 48.13] 0.95[0.02; 48.13]KEYNOTE-040 (all population), 201810%480NAnot evaluable Dyspnoea AE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 2.26 [0.58; 8.83] KEYNOTE-048 (PC vs C ; all population), 2019 1.39 [0.31; 6.28] 1.82[0.66; 4.99]KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 201920%1,150moderatenot evaluable Fatigue AE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.60 [0.26; 1.42] KEYNOTE-048 (PC vs C ; all population), 2019 1.52 [0.75; 3.08] 0.99[0.40; 2.45]KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019263%1,150moderatenot evaluable Febrile neutropenia AE (grade 3-4)detailed resultsKEYNOTE-048 (P vs C ; all population), 2019 0.03 [0.00; 0.47] KEYNOTE-048 (PC vs C ; all population), 2019 1.61 [0.84; 3.11] 0.27[0.01; 13.91]KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019287%1,150moderatenot evaluable0.05.01.0relative treatment effectwww.metaEvidence.org2024-06-01 14:17 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 276,103,277,102,109,278,101,192,114 - treatments: 847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons